The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone, please call the Myeloma Infoline on 0800 980 3332

Last update: 27/07/2023

There are currently 38 open trials. In 142 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 38 open trials

Step 3: View Details

Trial Title:

Belantamab as monotherapy or in combination with other treatments for myeloma (DREAMM-20)

Treatments:

belantamab (GSK2857914)
Belantamab Mafodotin (GSK2857916)
Lenalidomide (Revlimid®)
Dexamethasone

Myeloma stage:

Relapsed, Refractory, Newly Diagnosed

Trial phase:

I, II

Summary

Summary:

This trial is investigating the safety and effectiveness of belantamab, a monoclonal antibody, as monotherapy (on its own) or in combination with other treatments for the treatment of myeloma.

Locations

Locations:

Leicester Royal Infirmary, Leicester;
Churchill Hospital, Oxford

Who can enter the study?

Who can enter the study?:

There are different parts to this trial and they have different requirements.

Part 1: Relapsed and/or refractory myeloma patients who have received at least 3 previous lines of treatment including:

  • at least one immunomodulatory agent, such as lenalidomide (Revlimid®) and;
  • at least one proteasome inhibitor, such as bortezomib (Velcade®) and;
  • an anti-CD38 antibody, such as daratumumab (Darzalex®)

Part 2: Relapsed and/or refractory myeloma patients who have had at least one previous treatment.

Part 3: Newly diagnosed myeloma patients who are ineligible for transplant.

What's involved?

What's involved?:

Patients will be assigned to groups.

Different groups of patients will have belantamab administered to them at different doses and on different schedules, and/or in combination with other treatments including belantamab mafodotin (Blenrep®), lenalidomide (Revlimid®), dexamethasone or other appropriate Standard of Care treatment.

Patients will be required to attend outpatient clinics for regular check-ups and blood tests for up to 52 months (4 years and 4 months).

Clinical Information

Clinical Information
(for Medical Professionals):

A Phase 1/2 open-label, multicentre, dose escalation and expansion study to investigate the safety, tolerability, and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with myeloma

For more information, click here.

Find

Find out more about Myeloma UK:

Visit www.myeloma.org.uk

Do you want to talk to someone? Call our myeloma Infoline